Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
Objectives: This study aimed to evaluate the safety and immunogenicity of inactivated COVID-19 vaccines in patients with gastrointestinal cancer (GI) cancer. The role of memory B cells (MBCs) in the humoral response to COVID-19 vaccination was also investigated. Methods: In this prospective observat...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971222004465 |
| _version_ | 1798032511751684096 |
|---|---|
| author | Tong Li Rui Song Jingjie Wang Jianbo Zhang Hongxing Cai Hongmei He Wei Hu Dajun Yu Chuanhu Wang Qingbo Pan Mingli Peng Hong Ren Peng Zhu |
| author_facet | Tong Li Rui Song Jingjie Wang Jianbo Zhang Hongxing Cai Hongmei He Wei Hu Dajun Yu Chuanhu Wang Qingbo Pan Mingli Peng Hong Ren Peng Zhu |
| author_sort | Tong Li |
| collection | DOAJ |
| description | Objectives: This study aimed to evaluate the safety and immunogenicity of inactivated COVID-19 vaccines in patients with gastrointestinal cancer (GI) cancer. The role of memory B cells (MBCs) in the humoral response to COVID-19 vaccination was also investigated. Methods: In this prospective observational study, GI cancer patients and healthy individuals who had received 2 doses of inactivated COVID-19 vaccines were included. The data regarding adverse effects, serum anti-receptor binding domain (RBD)-IgG, neutralizing antibodies (NAbs), and frequencies of MBCs were collected prospectively. Results: The inactivated COVID-19 vaccines were safe and well tolerated. Serum anti-RBG-IgG and NAbs were lower for cancer patients. Old age, high ASA score, and receiving active chemotherapy were risk factors for lower antibody titers. The frequencies of activated and resting MBCs decreased in (17.45% vs 38.11%, P = 0.002; 16.98% vs 34.13%, P = 0.023), while the frequencies of intermediate and atypical MBCs increased in cancer patients (40.06% vs 19.87%, P = 0.010; 25.47% vs 16.61%, P = 0.025). The serum antibody titer decreased gradually during follow-up but increased when a booster vaccine was given. Conclusion: The inactivated COVID-19 vaccines were well tolerated in patients with GI cancer but with lower immunogenicity. The subpopulations of MBCs were disordered in cancer patients, and a booster vaccine may be prioritized for them. |
| first_indexed | 2024-04-11T20:15:06Z |
| format | Article |
| id | doaj.art-cdd26c3bb2d540078a4990137ab28f73 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-04-11T20:15:06Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-cdd26c3bb2d540078a4990137ab28f732022-12-22T04:05:00ZengElsevierInternational Journal of Infectious Diseases1201-97122022-09-01122874884Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancerTong Li0Rui Song1Jingjie Wang2Jianbo Zhang3Hongxing Cai4Hongmei He5Wei Hu6Dajun Yu7Chuanhu Wang8Qingbo Pan9Mingli Peng10Hong Ren11Peng Zhu12Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of General Surgery, The Renmin Hospital of Wushan country, Chongqing, ChinaDepartment of General Surgery, The Renmin Hospital of Wushan country, Chongqing, ChinaDepartment of General Surgery, The Renmin Hospital of Wushan country, Chongqing, ChinaKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; Hong Ren, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, 74 Linjiang Road, Yuzhong District, Chongqing 400010, China, Tel.: +86-023-63829629.Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; Corresponding author: Peng Zhu, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, 74 Linjiang Road, Yuzhong District, Chongqing 400010, China. Tel: +86-023-63693840.Objectives: This study aimed to evaluate the safety and immunogenicity of inactivated COVID-19 vaccines in patients with gastrointestinal cancer (GI) cancer. The role of memory B cells (MBCs) in the humoral response to COVID-19 vaccination was also investigated. Methods: In this prospective observational study, GI cancer patients and healthy individuals who had received 2 doses of inactivated COVID-19 vaccines were included. The data regarding adverse effects, serum anti-receptor binding domain (RBD)-IgG, neutralizing antibodies (NAbs), and frequencies of MBCs were collected prospectively. Results: The inactivated COVID-19 vaccines were safe and well tolerated. Serum anti-RBG-IgG and NAbs were lower for cancer patients. Old age, high ASA score, and receiving active chemotherapy were risk factors for lower antibody titers. The frequencies of activated and resting MBCs decreased in (17.45% vs 38.11%, P = 0.002; 16.98% vs 34.13%, P = 0.023), while the frequencies of intermediate and atypical MBCs increased in cancer patients (40.06% vs 19.87%, P = 0.010; 25.47% vs 16.61%, P = 0.025). The serum antibody titer decreased gradually during follow-up but increased when a booster vaccine was given. Conclusion: The inactivated COVID-19 vaccines were well tolerated in patients with GI cancer but with lower immunogenicity. The subpopulations of MBCs were disordered in cancer patients, and a booster vaccine may be prioritized for them.http://www.sciencedirect.com/science/article/pii/S1201971222004465COVID-19Inactivated vaccineMemory B cells |
| spellingShingle | Tong Li Rui Song Jingjie Wang Jianbo Zhang Hongxing Cai Hongmei He Wei Hu Dajun Yu Chuanhu Wang Qingbo Pan Mingli Peng Hong Ren Peng Zhu Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer International Journal of Infectious Diseases COVID-19 Inactivated vaccine Memory B cells |
| title | Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer |
| title_full | Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer |
| title_fullStr | Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer |
| title_full_unstemmed | Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer |
| title_short | Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer |
| title_sort | safety and immunogenicity of inactivated sars cov 2 vaccines in people with gastrointestinal cancer |
| topic | COVID-19 Inactivated vaccine Memory B cells |
| url | http://www.sciencedirect.com/science/article/pii/S1201971222004465 |
| work_keys_str_mv | AT tongli safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT ruisong safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT jingjiewang safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT jianbozhang safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT hongxingcai safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT hongmeihe safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT weihu safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT dajunyu safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT chuanhuwang safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT qingbopan safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT minglipeng safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT hongren safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer AT pengzhu safetyandimmunogenicityofinactivatedsarscov2vaccinesinpeoplewithgastrointestinalcancer |